Physician profile
Gary Jan Levin
NPI 1568499457
$947.59
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $165 · 2020: $230 · 2021: $374 · 2022: $179.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $451.57 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $107.07 | 2020-2021 | |
| Genentech USA, INC. | $80.59 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $52.18 | 2019-2021 | |
| Allergan, INC. | $41.04 | 2020 | |
| Sun Pharmaceutical Industries INC. | $39.15 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $38.48 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $31.55 | 2021 | |
| Alcon Vision LLC | $30.07 | 2019-2022 | |
| Alimera Sciences, INC. | $21.38 | 2021 | |
| Omeros Corporation | $19.73 | 2019 | |
| Beaver-Visitec International, INC. | $19.11 | 2021 | |
| Ocular Therapeutix, INC. | $15.67 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Levin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.